What Lanreotide is
Lanreotide is a long-acting somatostatin analog used in approved endocrine and neuroendocrine-tumor contexts.
Lanreotide is grouped under Approved / Clinical / Endogenous / Biology on PeptideFactCheck because it is a useful comparator to octreotide and shows how clinically important peptide analogs can be.
The useful starting point is to separate the molecule itself from the internet story around it. It is a useful comparator to octreotide and shows how clinically important peptide analogs can be.
Why people keep looking it up
It is a useful comparator to octreotide and shows how clinically important peptide analogs can be.
Lanreotide is a long-acting somatostatin analog used in approved endocrine and neuroendocrine-tumor contexts.
Lanreotide tends to stay in the conversation because it touches a familiar public theme: somatostatin analog, hormone suppression, and endocrine oncology. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved somatostatin analog with direct human evidence.
Human trials and labeling support specific approved uses.
Mechanism aligns with somatostatin receptor pharmacology.
Why this page carries the current tier: Approved somatostatin analog with direct human evidence.
The current seed trail for Lanreotide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Approved endocrine-oncology use should not be flattened into vague hormone-blocking language.
FDA-approved lanreotide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Lanreotide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Lanreotide is CID 6918011. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 6918011
- Formula
- C54H69N11O10S2
- Molecular weight
- 1096.3
- InChIKey
- PUDHBTGHUJUUFI-SCTWWAJVSA-N
Matched synonyms include Lanreotide, 108736-35-2, Ipstyl, Lanreotida, Lanreotidum, Lanreotide Autogel, BIM 23014, Bim-23014.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Lanreotide returns 117 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Lanreotide returns 1532 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Lanreotide Acetate
- Generic names
- LANREOTIDE ACETATE
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA215395
Indications and usage. 1 INDICATIONS AND USAGE Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improv...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Cholelithiasis and Complications of Cholelithiasis : Monitor periodically. Discontinue if complications of cholthiasis are suspected. Gallstones may occur; consider periodic monitoring. ( 5.1 ) Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. ( 5.2 , 7.1 ) Cardiovascular Abnormalities : Decrease in heart rate may occur. Use...
Contraindications. 4 CONTRAINDICATIONS Lanreotide Injection is contraindicated in patients with history of a hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide [ see Adverse Reactions ( 6.3 )] . Hypersensitivity to lanreotide. ( 4 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.